X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The medications under the agreement are Methotrexate Injection; Phytonadione Injectable Emulsion; Ceftriaxone for Injection; Labetalol Hydrochloride Injection; Midazolam Injection; Milrinone Lactate Injection; and Vancomycin Hydrochloride for Injection.
Lead Product(s): Methotrexate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 03, 2020
Details:
Baudax Bio has entered into a Pharmacy Supplier Agreement with Vizient, Inc. effective as of July 1, 2020, to offer ANJESO (meloxicam) injection, a non-opioid option for managing moderate to severe pain.
Lead Product(s): Meloxicam
Therapeutic Area: Neurology Product Name: Anjeso
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Baudax Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 20, 2020
Details:
Vizient has signed an agreement with Pfizer to add six drugs identified as “essential medications” to its Novaplus® Enhanced Supply Program, part of Vizient’s private label pharmacy solution.
Lead Product(s): Dexmedetomidine Hydrochloride
Therapeutic Area: Neurology Product Name: Precedex
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
